| SARS‐CoV‐2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells S Lukassen, RL Chua, T Trefzer, NC Kahn, MA Schneider, T Muley, ... The EMBO journal 39 (10), e105114, 2020 | 1118 | 2020 |
| Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline G Raghu, M Remy-Jardin, L Richeldi, CC Thomson, Y Inoue, T Johkoh, ... American Journal of Respiratory and Critical Care Medicine 205 (9), e18-e47, 2022 | 1027 | 2022 |
| Diagnosis of hypersensitivity pneumonitis in adults: an official ATS/JRS/ALAT clinical practice guideline G Raghu, M Remy-Jardin, CJ Ryerson, JL Myers, M Kreuter, M Vasakova, ... American journal of respiratory and critical care medicine 202 (3), e36-e69, 2020 | 679 | 2020 |
| Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial TM Maher, TJ Corte, A Fischer, M Kreuter, DJ Lederer, M Molina-Molina, ... The lancet Respiratory medicine 8 (2), 147-157, 2020 | 510 | 2020 |
| Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised … AU Wells, KR Flaherty, KK Brown, Y Inoue, A Devaraj, L Richeldi, T Moua, ... The lancet Respiratory medicine 8 (5), 453-460, 2020 | 434 | 2020 |
| Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype DR Bielenberg, Y Hida, A Shimizu, A Kaipainen, M Kreuter, CC Kim, ... The Journal of clinical investigation 114 (9), 1260-1271, 2004 | 356 | 2004 |
| Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled … J Behr, A Prasse, M Kreuter, J Johow, KF Rabe, F Bonella, R Bonnet, ... The Lancet Respiratory Medicine 9 (5), 476-486, 2021 | 293 | 2021 |
| Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis M Kreuter, S Ehlers-Tenenbaum, K Palmowski, J Bruhwyler, U Oltmanns, ... PloS one 11 (3), e0151425, 2016 | 289 | 2016 |
| Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry J Behr, M Kreuter, MM Hoeper, H Wirtz, J Klotsche, D Koschel, S Andreas, ... European Respiratory Journal 46 (1), 186-196, 2015 | 270 | 2015 |
| Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY trial C Vancheri, M Kreuter, L Richeldi, CJ Ryerson, D Valeyre, JC Grutters, ... American journal of respiratory and critical care medicine 197 (3), 356-363, 2018 | 259 | 2018 |
| The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements AM Hoffmann-Vold, TM Maher, EE Philpot, A Ashrafzadeh, R Barake, ... The Lancet Rheumatology 2 (2), e71-e83, 2020 | 250 | 2020 |
| Global incidence and prevalence of idiopathic pulmonary fibrosis TM Maher, E Bendstrup, L Dron, J Langley, G Smith, JM Khalid, H Patel, ... Respiratory research 22, 1-10, 2021 | 243 | 2021 |
| Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities PM George, P Spagnolo, M Kreuter, G Altinisik, M Bonifazi, FJ Martinez, ... The lancet Respiratory medicine 8 (9), 925-934, 2020 | 241 | 2020 |
| Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis M Kreuter, W Wuyts, E Renzoni, D Koschel, TM Maher, M Kolb, ... The Lancet Respiratory Medicine 4 (5), 381-389, 2016 | 232 | 2016 |
| Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON B Crestani, JT Huggins, M Kaye, U Costabel, I Glaspole, T Ogura, ... The Lancet Respiratory Medicine 7 (1), 60-68, 2019 | 224 | 2019 |
| Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study TM Drake, AB Docherty, EM Harrison, JK Quint, H Adamali, S Agnew, ... American journal of respiratory and critical care medicine 202 (12), 1656-1665, 2020 | 221 | 2020 |
| Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial G Raghu, B Van Den Blink, MJ Hamblin, AW Brown, JA Golden, LA Ho, ... Jama 319 (22), 2299-2307, 2018 | 221 | 2018 |
| Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo A Renz, WE Berdel, M Kreuter, C Belka, K Schulze-Osthoff, M Los Blood, The Journal of the American Society of Hematology 98 (5), 1542-1548, 2001 | 217 | 2001 |
| The therapy of idiopathic pulmonary fibrosis: what is next? V Somogyi, N Chaudhuri, SE Torrisi, N Kahn, V Müller, M Kreuter European Respiratory Review 28 (153), 2019 | 215 | 2019 |
| Palliative care in interstitial lung disease: living well M Kreuter, E Bendstrup, AM Russell, S Bajwah, K Lindell, Y Adir, ... The Lancet Respiratory Medicine 5 (12), 968-980, 2017 | 214 | 2017 |
Toby Michael MaherKeck Medicine of University of Southern CaliforniaVerified email at rbht.nhs.uk
